News
Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia
NEW YORK, Feb. 4, 2023 /PRNewswire/ — Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the U.S. Food...
Egret Therapeutics Announces the Addition of Three New Members to its Scientific Advisory Board
NEW YORK, Jan. 3, 2023 /PRNewswire/ — Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific Advisory...
Egret Therapeutics completes oversubscribed pre-A financing round
NEW YORK, Feb. 15, 2022 /PRNewswire/ — Egret Therapeutics, a clinical-stage biotherapeutics company focused on the treatment of neurological diseases, announced today the completion of its pre-A financing....
